Compass Pathways (CMPS) Climbs 17.02% on August 5
Equities Staff Follow |Compass Pathways Plc - ADR (NASDAQ: CMPS) has climbed $2.73 (17.02%) and is currently sitting at $18.84, as of 11:50:10 est on August 5.
396,224 shares have traded hands.
The Company is up 8.16% over the last 5 days and shares advanced 52.97% over the last 30 days.
Compass Pathways expects its next earnings on 2022-08-10.
For technical charts, analysis, and more on Compass Pathways visit the company profile.
About Compass Pathways Plc - ADR
COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Its focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. It is pioneering the development of a new model of psilocybin therapy, in which its proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and it is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. It is headquartered in London, UK, with offices in New York, USA. Its vision is a world of mental wellbeing.
To get more information on Compass Pathways Plc - ADR and to follow the company's latest updates, you can visit the company's profile page here: Compass Pathways Plc - ADR's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.
Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer